logo

GRI

GRI BioยทNASDAQ
--
--(--)
--
--(--)

GRI Profile

Gri Bio, Inc.

A clinical-stage biopharmaceutical company that develops novel drugs to deter abuse in the treatment of central nervous system disorders

Pharmaceutical
01/11/2018
02/10/2021
NASDAQ Stock Exchange
3
12-31
Common stock
2223 Avenida de la Playa, #208, La Jolla, CA 92037
--
GRI Bio, Inc. was incorporated under the laws of the State of Delaware on January 11, 2018. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for serious diseases associated with the dysfunctional immune response leading to inflammation, fibrosis and autoimmune diseases. The company's goal is to become an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.